Data Sheet (Cat.No.T26693)

TargetMol

AVX-001

Chemical Properties



CAS No. : 300553-18-8

Formula: C21H29F3OS

Molecular Weight: 386.51

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	AVX-001, a cytosolic phospholipase A2 (cPLA2) inhibitor, is used potentially for the treatment of psoriasis.
Targets(IC50)	Others,Phospholipase

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5873 mL	12.9363 mL	25.8726 mL
5 mM	0.5175 mL	2.5873 mL	5.1745 mL
10 mM	0.2587 mL	1.2936 mL	2.5873 mL
50 mM	0.0517 mL	0.2587 mL	0.5175 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Omland SH, Habicht A, Damsbo P, Wilms J, Johansen B, Gniadecki R. A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 Jan 20. doi: 10.1111/jdv.14128. [Epub ahead of print] PubMed PMID: 28107559.

Huwiler A, Feuerherm AJ, Sakem B, Pastukhov O, Filipenko I, Nguyen T, Johansen B. The ω3-polyunsaturated fatty acid derivatives AVX001 and AVX002 directly inhibit cytosolic phospholipase A(2) and suppress PGE(2) formation in mesangial cells. Br J Pharmacol. 2012 Dec;167(8):1691-701. doi: 10.1111/j.1476-5381.2012.02114.x. PubMed PMID: 22831644; PubMed Central PMCID: PMC3525871.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481